Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 60

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 4
Chunk 60
---
0.20 per share, or the Ordinary Shares, and (ii) pre-funded warrants, or the Pre-Funded Warrants, to purchase up to 1,427,308 Ordinary
                                              Shares, generating $5.5 million in gross proceeds.                                          
------------------------------------------------------------------------------------------------------------------------------------------
Lavie Bio
 

◾   Collaboration Agreement (February 2024) - Lavie Bio entered into an agreement for the discovery and development of new biological
                                          insecticidal solutions with Syngenta Crop Protection.                                      
-------------------------------------------------------------------------------------------------------------------------------------

◾    Licensing Agreement (February 2024) – Lavie Bio secured the second half advance payment of $2.5 million after meeting Corteva’s 
    licensing agreement requirements. This payment signifies the completion of a $5 million advance payment outlined in the licensing
                                                      agreement signed in July 2023.                                                 
-------------------------------------------------------------------------------------------------------------------------------------

◾   Sustainability (March 13) - Ceres Global Ag Corp. has chosen to include Lavie Bio’s Yalos bio-inoculant, in regenerative agriculture
                                                       initiatives in North America.                                                    
----------------------------------------------------------------------------------------------------------------------------------------

◾   Joint Validation Trials (March 2024) – Lavie Bio extended its joint validation trials for its biofungicides conducted by Bayer
                                  AG, after successful first-year laboratory and greenhouse testing.                              
----------------------------------------------------------------------------------------------------------------------------------

◾       Pipeline (July 2024) - Lavie Bio announced the commercial expansion of Yalos to    
    winter wheat and will commence sales across the United States for the 2024-2025 season.
-------------------------------------------------------------------------------------------

◾      Collaboration Agreement (July 2024) - Lavie Bio announced a significant milestone in its collaboration with ICL Group Ltd. to develop   
    bio-stimulant solutions for key row crops facing extreme weather conditions by leveraging AI to identify over a dozen novel microbes within
                                                                     12 months.                                                                
-----------------------------------------------------------------------------------------------------------------------------------------------

◾          Grant (September 2024) – Lavie Bio received a grant from the IIA, to advance its program to develop a technology for the delivery        
                                  of ag-biologicals to agriculture. This patented technology, named ‘MicroFermentor’,                               
    is based on an innovative microbe formulation that enables the multiplication of beneficial bacteria directly on the plant, reducing application
                             costs, extending shelf life, and prolonging the bacteria's viability after field application.                          
----------------------------------------------------------------------------------------------------------------------------------------------------

◾   Pipeline (November 2024) - Lavie Bio announced commercial expansion of Yalos® as seed-treatment for